Andrew Eschenbach

Dr. Andrew von Eschenbach is an angel investor. He, currently, serves as President of Samaritan Health Initiatives and as an Adjunct Professor at University of Texas MD Anderson Cancer Center. He serves as the Board Member at HistoSonics. He is also a Board Member at COTA and Innocrin Pharmaceuticals. From September of 2005 to January 2009 he served as Commissioner of Food and Drugs where he championed an agenda to modernize the FDA by process improvement of the regulatory pathway for drugs and medical devices and by fostering creative projects, including FDA's Critical Path Initiative (designed to bring modern tools of science to the product development process)